DISCOUNT-ZERTIFIKAT - MODERNA | Market Closed - Deutsche Boerse AG 15:51:01 2024-06-12 EDT | ||
| 101.6 EUR | -0.55% |
|
| Current month | +0.74% | ||
| 1 month | +2.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 101.6 | -0.55% |
| 24-06-11 | 102.2 | +0.19% |
| 24-06-10 | 102 | +0.37% |
| 24-06-07 | 101.6 | +0.84% |
| 24-06-06 | 100.8 | -0.08% |
Delayed Quote Deutsche Boerse AG
Last update June 12, 2024 at 03:51 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SV745N |
| ISIN | DE000SV745N7 |
| Date issued | 2023-06-30 |
| Maturity | 2024-06-21 (9 Days) |
| Parity | 1 : 1 |
| Emission price | 83.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.3 € |
|---|---|
| Lowest since issue | 61.35 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
147.7
USD
Average target price
145.2
USD
Spread / Average Target
-1.72%
- Stock Market
- Certificates
- Certificat
